126 related articles for article (PubMed ID: 23692521)
1. Modeling phospholipidosis induction: reliability and warnings.
Goracci L; Ceccarelli M; Bonelli D; Cruciani G
J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521
[TBL] [Abstract][Full Text] [Related]
2. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
3. Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M; Tripal P; Roas F; Kornhuber J
ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
[TBL] [Abstract][Full Text] [Related]
4. How does the quality of phospholipidosis data influence the predictivity of structural alerts?
Przybylak KR; Alzahrani AR; Cronin MT
J Chem Inf Model; 2014 Aug; 54(8):2224-32. PubMed ID: 25062434
[TBL] [Abstract][Full Text] [Related]
5. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
6. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M
Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557
[TBL] [Abstract][Full Text] [Related]
7. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Fischer H; Atzpodien EA; Csato M; Doessegger L; Lenz B; Schmitt G; Singer T
J Med Chem; 2012 Jan; 55(1):126-39. PubMed ID: 22122484
[TBL] [Abstract][Full Text] [Related]
8. pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery.
Balogh GT; Müller J; Könczöl A
Eur J Pharm Sci; 2013 Apr; 49(1):81-9. PubMed ID: 23439241
[TBL] [Abstract][Full Text] [Related]
9. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
10. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
Almela MJ; Torres PA; Lozano S; Herreros E
Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
[TBL] [Abstract][Full Text] [Related]
12. Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
Alakoskela JM; Vitovic P; Kinnunen PK
ChemMedChem; 2009 Aug; 4(8):1224-51. PubMed ID: 19551800
[TBL] [Abstract][Full Text] [Related]
13. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
Orogo AM; Choi SS; Minnier BL; Kruhlak NL
Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
[TBL] [Abstract][Full Text] [Related]
14. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals.
Jiang Z; Reilly J
J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505
[TBL] [Abstract][Full Text] [Related]
15. Predicting myelosuppression of drugs from in silico models.
Crivori P; Pennella G; Magistrelli M; Grossi P; Giusti AM
J Chem Inf Model; 2011 Feb; 51(2):434-45. PubMed ID: 21275392
[TBL] [Abstract][Full Text] [Related]
16. A strategy for risk management of drug-induced phospholipidosis.
Chatman LA; Morton D; Johnson TO; Anway SD
Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
[TBL] [Abstract][Full Text] [Related]
17. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
18. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
19. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
20. Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro Screen.
Fusani L; Brown M; Chen H; Ahlberg E; Noeske T
Mol Pharm; 2017 Dec; 14(12):4346-4352. PubMed ID: 29077420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
